In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, R&D directors, and marketing directors from producers of nutritional supplements, pharmaceutical businesses creating enzyme therapy, and manufacturers of gluten-free foods were examples of supply-side sources. Board-certified gastroenterologists, allergists, registered dietitians, nutritionists, pediatric specialists, hospital pharmacy procurement leads, retail pharmacy directors, supermarket category managers, and representatives of patient advocacy groups were among the demand-side sources. In addition to gathering information on clinical adoption patterns, consumer purchasing behavior, pricing strategies, reimbursement dynamics, and distribution channel preferences, primary research validated market segmentation across treatment types and confirmed product pipeline timelines for emerging enzyme therapies.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Global market valuation was derived through revenue mapping and consumption volume analysis. The methodology included:
Identification of 50+ key manufacturers and brands across North America, Europe, Asia-Pacific, and Latin America specializing in gluten-free products, enzyme therapies, and nutritional supplements
Product mapping across dietary management (gluten-free foods), pharmaceuticals (enzyme therapies, investigational drugs), and nutritional supplements (probiotics, vitamins, minerals) categories
Analysis of reported and modeled annual revenues specific to gluten intolerance treatment portfolios
Coverage of manufacturers representing 72-78% of global market share in 2024
Extrapolation using bottom-up (patient population × treatment adoption rate × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across treatment types, distribution channels, patient demographics, and formulation types